Scotiabank raised the firm’s price target on Arcellx (ACLX) to $133 from $82 and keeps an Outperform rating on the shares. The firm adjusted its model following “highly compelling results” reported ...

Arcellx (NASDAQ:ACLX – Free Report) had its price target raised by Piper Sandler from $91.00 to $115.00 in a report issued on ...

Scotiabank analyst George Farmer reiterated a Buy rating on Arcellx Inc (ACLX – Research Report) today and set a price target of $133.00. The company’s shares closed last Friday at $103.06. Farmer ...

Arcellx (NASDAQ:ACLX – Free Report) had its price objective boosted by Bank of America from $84.00 to $100.00 in a research ...

Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.81 per share a year ago. These figures are ...

Arcellx (ACLX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

On Tuesday, Arcellx Inc (ACLX) stock saw a modest uptick, ending the day at $87.12 which represents a slight increase of $0.68 or 0.79% from the prior close of $86.44. The stock opened at $80.22 and ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, ...

During the last three months, 7 analysts shared their evaluations of Arcellx ACLX +4.99% Get Free Report , revealing diverse ...

Stifel has upgraded Alkermes (ALKS) to buy from hold, citing increased confidence in the company’s narcolepsy drug candidate ALKS2680. Read more here.